Safety of biologics in severe asthmatic patients with SARS-CoV-2 infection: A prospective study

7^th International Conference on PHARMACEUTICS & ADVANCED DRUG DELIVERY SYSTEMS

March 27-28, 2023 | London, UK

Manti S

University of Messina, Italy

Keynote: J Med Chem

Abstract :

Background: Asthma guidelines have recommended continuing treatment with biologics during coronavirus disease 2019 (COVID-19) pandemic. However, a continuation of treatment with biologics in patients with severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) has been little investigated. Objective: To assess the safety of biologics in patients with SARS-CoV-2 infection. Methods: A pilot, monocentric, prospective study. Patients aged 6 years old and older with severe asthma on treatment with biologics and confirmed SARS-CoV-2 infection were enrolled. Patients were followed-up with periodic calls at different time points up to 3 months to detect any adverse effect and its relationship with biologic treatment according to the Naranjo Adverse Probability Scale (NAPS). The severity of SARS-CoV-2 infection and clinical outcome were also assessed. Results: Overall, we included 21 patients (10 on therapy with omalizumab, 9 with dupilumab, and 2 with mepolizumab). Only a patient-reported two local adverse events. No other adverse event was reported. Twenty out of 21 patients had a mild COVID-19 course, and no adverse outcome was observed. Conclusion: We showed that the scheduled dose of the biologic therapy can be administered safely on time in patients with SARS-CoV-2 infection, as the treatment did not result in adverse events or outcomes. Recent publications 1. UPDATE - 2022 Italian guidelines on the management of bronchiolitis in infants 2. Effects of Elexacaftor/Tezacaftor/Ivacaftor on Cardiorespiratory Polygraphy Parameters and Respiratory Muscle Strength in Cystic Fibrosis Patients with Severe Lung Disease 3. Vascular Endothelial Growth Factor as Molecular Target for Bronchopulmonary Dysplasia Prevention in Very Low Birth Weight Infants

Biography :

Manti S, Giallongo is an MD, Pediatrician, PhD, University Resercher at Pediatric Unit, Dept of Human and Pediatric Pathology "Gaetano Barresi", University of Messina, Messina, Italy. She received National habilitation (ASN) as Full Professor in Pediatrics, SSD 06/G1. She received National habilitation (ASN) as Associate Professor in Pediatrics, SSD 06/G1. She received her doctor of medicine degree from the University of Messina, Italy. She was graduated as Pediatric Specialist at the University of Messina, Italy She earned her PhD and Doctor Europaeus in 2018 in “Biotechnology in Medicine and Surgery”, University of Messina, Messina, Sicily, Italy. Her research experience is focused on allergology and pulmonology in the paediatric population.